Nephros (NEPH) Cash from Operations Growth (3y) (2013 - 2026)
Powered by 
Analysis
Nephros (NEPH) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 178.01 Bn | 172.41 Bn | 7.27 Bn | 27.41% |
| 2 | Intuitive Surgical | 131.29 Bn | 126.08 Bn | 1.96 Bn | 16.81% |
| 3 | Medtronic | 116.38 Bn | 107.56 Bn | 6.34 Bn | 27.02% |
| 4 | Stryker | 106.01 Bn | 102.53 Bn | 4.50 Bn | 22.38% |
| 5 | Boston Scientific | 63.40 Bn | 62.86 Bn | 3.85 Bn | 30.85% |
| 6 | Edwards Lifesciences | 48.89 Bn | 44.64 Bn | 1.35 Bn | 168.71% |
| 7 | Alcon | 32.59 Bn | 31.13 Bn | 1.68 Bn | 16.21% |
| 8 | Dexcom | 31.84 Bn | 29.89 Bn | 830.00 Mn | 12.26% |
| 9 | Steris | 20.61 Bn | 20.13 Bn | 684.20 Mn | 9.30% |
| 10 | Nephros | 48.31 Mn | 43.62 Mn | 4.03 Mn | 44.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.44% |
| Mar 31, 2026 | -100.45% |
| Dec 31, 2025 | 43.40% |
| Sep 30, 2025 | 37.20% |
| Jun 30, 2025 | 43.05% |
| Mar 31, 2025 | 29.65% |
| Dec 31, 2024 | 80.62% |
| Sep 30, 2024 | 11.86% |
| Jun 30, 2024 | -62.39% |
| Mar 31, 2024 | -130.32% |
| Dec 31, 2023 | 43.65% |
| Sep 30, 2023 | 32.56% |
| Jun 30, 2023 | 28.69% |
| Mar 31, 2023 | 29.07% |
| Dec 31, 2022 | -36.36% |
| Sep 30, 2022 | 34.82% |
| Jun 30, 2022 | 6.91% |
| Mar 31, 2022 | -37.12% |
| Dec 31, 2021 | 14.07% |
| Sep 30, 2021 | 6.74% |